The HFE protein (Homeostatic Iron Regulator) is a membrane protein that plays a critical role in systemic iron metabolism. Mutations cause hereditary hemochromatosis and are associated with increased risk of neurodegenerative diseases due to iron accumulation in the brain.
| Protein Name | Homeostatic Iron Regulator (HFE) |
|---|
| Gene | HFE |
|---|
| UniProt ID | Q30201 |
|---|
| Molecular Weight | ~40 kDa |
|---|
| Subcellular Localization | Cell membrane, Endoplasmic reticulum |
|---|
| Protein Family | MHC class I family |
|---|
The HFE protein (Homeostatic Iron Regulator) is a 348-amino acid transmembrane protein that functions as a key regulator of iron homeostasis in the body. Initially discovered as the protein defective in hereditary hemochromatosis, HFE has since been implicated in neurodegenerative diseases through its effects on brain iron metabolism. The protein is structurally related to major histocompatibility complex (MHC) class I molecules but does not present antigens; instead, it functions in iron sensing and regulation.
¶ Domain Architecture
| Domain |
Description |
Function |
| Alpha-1 domain |
N-terminal extracellular |
Protein-protein interactions |
| Alpha-2 domain |
Extracellular |
Ligand binding |
| Alpha-3 domain |
Extracellular |
Binds beta-2-microglobulin |
| Transmembrane domain |
Single helix |
Membrane anchoring |
| Cytoplasmic tail |
Intracellular |
Intracellular signaling |
- MHC-like fold: HFE shares the characteristic MHC class I three-domain structure.
- Beta-2-microglobulin binding: Required for proper folding and cell surface expression.
- Transferrin receptor interaction site: The alpha-1 and alpha-2 domains mediate binding to TfR1.
- Cysteine residues: Form disulfide bonds important for structural stability.
- N-linked glycosylation: Multiple sites for carbohydrate attachment.
- Palmitoylation: May affect membrane localization.
- Phosphorylation: Potential regulatory sites.
- Iron sensing: HFE monitors body iron status through interaction with transferrin receptor 1 (TfR1) on cell surfaces.
- Hepcidin regulation: HFE is essential for appropriate hepcidin expression in response to body iron levels.
- Intestinal absorption: By controlling hepcidin, HFE regulates dietary iron uptake in the duodenum.
- Cellular iron uptake: Modulates transferrin-mediated iron uptake via TfR1.
- High expression: Liver, small intestine (duodenum), spleen, heart.
- Moderate expression: Brain (neurons, microglia, endothelial cells).
- Cellular localization: Primarily plasma membrane and endoplasmic reticulum.
Mutations in HFE cause the most common form of hereditary hemochromatosis (type 1):
- C282Y mutation: Most common pathogenic variant; disrupts disulfide bond, prevents proper folding.
- H63D mutation: Mild functional impairment; incomplete penetrance.
- S65C mutation: Rare; mild functional effect.
- Iron accumulation: Elevated iron in AD brain regions (hippocampus, basal ganglia).
- Mechanisms: Iron promotes amyloid-beta aggregation, oxidative stress, neuronal death.
- Evidence: HFE variants associated with increased AD risk in some populations.
- Substantia nigra: Iron accumulation is a hallmark of PD pathology.
- Dopaminergic neurons: Particularly vulnerable to iron-induced oxidative damage.
- HFE variants: May modify PD onset age and severity.
- Amyotrophic Lateral Sclerosis: Iron dysregulation in motor neurons.
- Multiple System Atrophy: Iron accumulation in putamen and cerebellum.
- NBIA: Iron accumulation disorders.
- Oxidative stress: Iron catalyzes Fenton reactions, generating reactive oxygen species.
- Protein aggregation: Iron promotes aggregation of amyloid-beta, alpha-synuclein, tau.
- Mitochondrial dysfunction: Iron accumulation impairs mitochondrial function.
- Inflammation: Iron activates microglia and promotes neuroinflammation.
- ** Ferroptosis**: Iron-dependent programmed cell death pathway.
| Drug |
Route |
BBB Penetration |
Clinical Use |
| Deferoxamine |
IV/SC |
Limited |
FDA approved |
| Deferasirox |
Oral |
Moderate |
FDA approved |
| Deferiprone |
Oral |
Good |
Trials for PD/AD |
- HFE gene therapy: AAV-mediated delivery.
- Hepcidin modulators: Therapeutic targeting of the HFE-hepcidin pathway.
- Antioxidants: Neuroprotective strategies.
- Ferroptosis inhibitors: Liproxstatin-1, ferrostatin-1.
- Hfe knockout mice: Spontaneous iron accumulation; useful for studying iron's role in neurodegeneration.
- Hfe/APP double transgenic: Synergistic effects on amyloid pathology and oxidative stress.
- Hfe/alpha-synuclein models: Investigate iron in synucleinopathies.
- Feder JN, et al. (1996). "A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis." Nat Genet. PMID:8780523
- Pietrangelo A. (2010). "Hereditary hemochromatosis: pathogenesis, diagnosis, and therapy." Gastroenterology. PMID:20153498
- Nandar W, Connor JR. (2011). "HFE gene variants affect iron in the brain." J Nutr. PMID:21957135
- Müller-Lehn CS, et al. (2023). "HFE variants and Alzheimer's disease risk." Neurology. PMID:36758471
- Wang J, et al. (2022). "Iron metabolism in neurodegenerative diseases." Neural Regen Res. PMID:34522664